GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Auro Laboratories Ltd (BOM:530233) » Definitions » Price-to-Owner-Earnings

Auro Laboratories (BOM:530233) Price-to-Owner-Earnings : 25.16 (As of May. 16, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Auro Laboratories Price-to-Owner-Earnings?

As of today (2025-05-16), Auro Laboratories's share price is ₹259.10. Auro Laboratories's Owner Earnings per Share (TTM) ended in Mar. 2024 was ₹10.30. It's Price-to-Owner-Earnings for today is 25.16.


The historical rank and industry rank for Auro Laboratories's Price-to-Owner-Earnings or its related term are showing as below:

BOM:530233' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.37   Med: 12.27   Max: 27.05
Current: 23.15

During the past 13 years, the highest Price-to-Owner-Earnings of Auro Laboratories was 27.05. The lowest was 2.37. And the median was 12.27.


BOM:530233's Price-to-Owner-Earnings is ranked better than
51.58% of 444 companies
in the Drug Manufacturers industry
Industry Median: 24.275 vs BOM:530233: 23.15

As of today (2025-05-16), Auro Laboratories's share price is ₹259.10. Auro Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹5.68. Therefore, Auro Laboratories's PE Ratio (TTM) for today is 45.62.

As of today (2025-05-16), Auro Laboratories's share price is ₹259.10. Auro Laboratories's EPS without NRI for the trailing twelve months (TTM) ended in was ₹5.68. Therefore, Auro Laboratories's PE Ratio without NRI for today is 45.62.

During the past 13 years, Auro Laboratories's highest PE Ratio without NRI was 46.48. The lowest was 3.37. And the median was 14.04.


Auro Laboratories Price-to-Owner-Earnings Historical Data

The historical data trend for Auro Laboratories's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Auro Laboratories Price-to-Owner-Earnings Chart

Auro Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.60 6.34 - - 15.64

Auro Laboratories Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 15.64 - - -

Competitive Comparison of Auro Laboratories's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Auro Laboratories's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Auro Laboratories's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Auro Laboratories's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Auro Laboratories's Price-to-Owner-Earnings falls into.


;
;

Auro Laboratories Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Auro Laboratories's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=259.10/10.30
=25.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Auro Laboratories  (BOM:530233) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Auro Laboratories Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Auro Laboratories's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Auro Laboratories Business Description

Traded in Other Exchanges
N/A
Address
S.K. Ahire Marg, 314, 3rd Floor, T.V. Industrial Estate, Worli, Mumbai, MH, IND, 400 030
Auro Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and selling of pharmaceutical products like Metformin Hydrochloride and Glibenclamide. The pharmaceutical products range offered by the company are anti-diabetic, muscle relaxant, diuretic, iron deficiency anti-fungal, anti-ulcer, iodine supplement, anti-malaria, antacids, anti-inflammatory, specialty chemicals, and others. The company sells its products in India and also exports it to international countries.

Auro Laboratories Headlines

No Headlines